This slide show features various images of papillary, clear cell, chromophobe, and tubulocystic renal cell carcinoma.
Stereotactic Radiation Appears Effective in Primary Renal Cell Cancer
Findings from a phase 2 trial highlight an acceptable adverse effect profile and renal function with stereotactic ablative body radiotherapy in primary renal cell cancer.
Oncology On-The-Go Podcast: Integrative and Palliative Kidney Cancer Care
Santosh Rao, MD, discusses the formation of new guidelines informing the use of integrative oncology for patients with kidney cancer from the Society for Integrative Oncology.
Pembrolizumab Improves DFS Vs Observation in Muscle-Invasive Urothelial Carcinoma
Interim findings from a phase 3 trial support adjuvant pembrolizumab as a new therapeutic option for those with muscle-invasive urothelial carcinoma at high risk of recurrence.
OncView™ Podcast: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management in Metastatic RCC
In an OncView™ program, David H. Aggen, MD, PhD, Robert S. Alter, MD, Arnab Basu, MD, MPH, FACP, Mehmet Asim Bilen, MD, and Chung-Han Lee, MD, MPH, offer their expert insights for the treatment of RCC.
Enfortumab Vedotin Combo Improves Outcomes in Urothelial Cancer Subgroups
Benefits with enfortumab vedotin plus pembrolizumab in prespecified patient subgroups with urothelial carcinoma in the EV-302 trial appear to be consistent with outcomes in the overall study population.
Olaparib Combo Improves Survival Vs Placebo in Metastatic CRPC
Findings from the phase 3 PROpel trial suggest that olaparib plus abiraterone acetate may help patients with metastatic castration-resistant prostate cancer live longer, according to Neal Shore, MD, FACS.